Aventis Ketek Approved By FDA; Antibiotic Launch Planned For Late July
This article was originally published in The Pink Sheet Daily
Executive Summary
Telithromycin is approved for the treatment of acute exacerbation of chronic bronchitis, acute bacterial sinusitis, and mild-to-moderate community acquired pneumonia. Phase IV commitments include pediatric studies in CAP and sinusitis.
You may also be interested in...
Sanofi-Aventis Voluntarily Pauses Ketek Pediatric Trials Pending FDA Consultation
The decision to stop pediatric studies of the antibiotic was not at FDA’s request or due to safety concerns, the company says.
Sanofi-Aventis Voluntarily Pauses Ketek Pediatric Trials Pending FDA Consultation
The decision to stop pediatric studies of the antibiotic was not at FDA’s request or due to safety concerns, the company says.
Sanofi’s Ketek Is New Target Of Congressional Scrutiny Of FDA
Sen. Grassley requests that senior CDER staff address allegations of inappropriate approval of Sanofi-Aventis’ antibiotic Ketek in May 1 letter.